Trial intelligence / Profile preview

Cadazolid versus vancomycin for Clostridium difficile-associated diarrhea

2013-002528-17Phase 3Completed

Sponsor
Actelion Pharmaceuticals Ltd
Start
Dec 2013
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
Countries
1
01

Overview

Phase 3, randomised, double-blind trial of cadazolid in Clostridioides difficile colitis (CDI) (2 arms), sponsored by Actelion Pharmaceuticals Ltd. Primary endpoint: Clinical Cure. Started Dec 2013; status: completed.

02

Drugs

cadazolid
03

Conditions

Clostridioides difficile colitis (CDI)

Beyond the preview

Go deeper on 2013-002528-17.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2013-002528-17.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call